Contineum Therapeutics (NASDAQ:CTNM) Now Covered by Stifel Nicolaus

Equities research analysts at Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research note issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $29.00 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 87.70% from the stock’s current price.

Contineum Therapeutics Price Performance

NASDAQ:CTNM opened at $15.45 on Tuesday. Contineum Therapeutics has a 52 week low of $13.90 and a 52 week high of $16.06.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).